Skip to content

The value of the Low-Intensity Extracorporeal Shockwave Therapy on the recovery of erectile function after nerve-sparing radical prostatectomy

The value of the Low-Intensity Extracorporeal Shockwave Therapy on the recovery of erectile function after nerve-sparing radical prostatectomy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035770
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ED caused by radical prostatectomy

Interventions

Experimental group:receive small dose PDE5 inhibitor + Low-Intensity Extracorporeal Shockwave Therapy
Control group:receive small dose PDE5 inhibitor

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. The patients who received nerve-sparing radical prostatectomy; 2. The surgeon who have conducted more than 100 radical prostatectomy one year and mastered bilateral standard Walsh nerve-sparing radical prostatectomy; 3. Aged 40 to 70 years and had normal sexual function; 4. The pTNM satge was pT2 or earlier stage; 5. The patients did not receive PDE5i 4 weeks before incusion; 6. The patients have stable physical relationship, and tried sextual activity more than 3 times; 7. The patients shoud not receive the other ED treatment during the study and follow-up period.

Exclusion criteria

Exclusion criteria: 1. Any instable mental disease, spinal injuries, and penile anatomic abnormality; 2. Have other cancers within 5 years; 3. Chronic blood systemic diseases; 4. Instable blood pressure(systolic blood pressure>160mmHg and diastolic blood pressure>100mmHg); 5. Instable blood glucoseHbA1c>13%; 6. Receive ADT therapy; 7. Receive pelvic radiotherapy; 8. Severe coagulopathy and receive anticoagulants(such as coumadin); 9. The researchers did not think the patients were suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
The result of NPTR;

Countries

China

Contacts

Public ContactSu Hengchuan

Fudan University Shanghai Cancer Center

suhengchuan@163.com+86 15901706579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026